← Back to Search

Small Molecule Drug

Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Hossein Borghaei, DO
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights

Study Summary

This trial is studying a new lung cancer drug to see if it shrinks tumors before surgery. Doctors will enroll 25 patients who have not had lung cancer treatment before and are healthy enough for surgery.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major pathologic response
Secondary outcome measures
Determine the safety, feasibility and tolerability of neoadjuvant sotorasib therapy in patients with surgically resectable KRAS G12C mutant NSCLC

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
227 Previous Clinical Trials
37,509 Total Patients Enrolled
Hossein Borghaei, DOPrincipal InvestigatorFox Chase Cancer Center
3 Previous Clinical Trials
93 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What have been the safety results of administering Sotorasib, 960 mg orally for a duration of 28 days?

"Our evaluation of Sotorasib, 960 mg administered orally daily for a 4-week period yielded a score of 2 due to the limited supporting evidence regarding its efficacy in Phase 2 trials."

Answered by AI

Does this research project have any open slots for participants?

"Affirmative. According to clinicaltrials.gov, recruitment for this trial is occurring presently; it was first posted on July 13th 2022 and last updated on the 29th of the same month. The team needs to recruit 25 participants from a single centre."

Answered by AI

What is the quota for participants in this medical trial?

"Affirmative. Clinicaltrials.gov data indicates that this clinical research is currently looking for participants, having been listed on July 13th 2022 and last updated on the 29th of July 2022. The study requires 25 volunteers across 1 site to be enrolled."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
2022. "Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05400577.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top